 |
||||||
|
||||||
 |
|
|
|||||||||||||||||||||||||||||
|
Monday, April 7 — 3:15 PM-5:15 PM San Diego Convention Center — Room 25A |
|
|
Chaired: |
Shaila Basavappa, Takeda Pharmaceuticals North America, Inc. |
This symposium will focus on two GI disorders that affect ~15-25% of the US population. Irritable Bowel Syndrome (IBS) has three forms, diarrhea predominant, constipation predominant and alternating (or mixed). The pathophysiology of IBS is presently unclear, however the enteric nervous system (ENS) maybe altered. Similarly, the exact mechanisms leading to chronic constipation are not well understood. On average, most chronic constipation patients have been suffering for over 5 years. Recent investigations have demonstrated that during IBS and chronic constipation bowel motility is significantly altered. Novel treatments utilizing GI physiology have been approved and/or in the pipeline to treat these debilitating disorders.
The goals of the proposed symposium are:
-
To gain a better understanding of IBS and chronic constipation
-
What are the proposed mechanisms? Is there a genetic component?
-
What are the present treatments and their mechanism of action and efficacy?
-
What treatments are in the pipeline?
|
3:15 PM |
Enteric nervous system and IBS and
constipation. |
|
3:45 PM |
IBS and chronic constipation: clinical
studies and treatments. |
|
4:15 PM |
Treating chronic constipation and IBS-C:
The role of ClC-2. |
|
4:45 PM |
Guanylate cyclase C activation restores GI
function. |